Background/aims: H. pylori eradication therapy has been widely performed. In addition, the number of patients with type 2 diabetes is increasing worldwide. The aim of this study was to understand the influence of H. pylori eradication therapy on the management of type 2 diabetes.
Methodology: A total of 174 patients with type 2 diabetes who did not have an active peptic ulcer or serious complications and were cured successfully of their H. pylori infection at our institute were included in this study. The time course of mean glycosylated hemoglobin (HbA1c) values and body mass index (BMI) during the year before and after H. pylori eradication were assessed by a paired Student's t-test.
Results: No significant changes in mean HbA1c values were observed during the year before or after eradication. However, the mean BMI, which did not change during the year before eradication, increased significantly at 6 months (23.1±2.6kg/m2, p<0.05) and 12 months (23.1±2.7kg/m2, p<0.05) after eradication as compared with the time point of eradication (22.9±2.6kg/m2).
Conclusions: H. pylori eradication significantly increased BMI but not HbA1c in patients with type 2 diabetes, despite diabetes treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5754/hge11960 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Achille Tendon Rupture After Treatment of Levofloxacin for Helicobacter pylori Eradication: A Case Report.
J Am Podiatr Med Assoc
January 2025
†Division of Geriatrics, Department of Internal Medicine, Marmara University Medical School, Pendik, Istanbul, Turkey.
This case report aims to demonstrate a rare occurrence of tendon rupture attributable to levofloxacin use in Helicobacter pylori eradication. On the seventh day of treatment, the patient experienced severe foot pain and difficulty in walking, leading to a diagnosis of Achilles tendon rupture confirmed through magnetic resonance imaging. Levofloxacin-induced tendinopathy and/or rupture are rare complications that are often linked to age and sex.
View Article and Find Full Text PDFShould Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Helicobacter
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Background And Aim: Although standard triple therapy remains the first-line eradication treatment for H. pylori worldwide, it is unclear whether metronidazole should be included empirically in second-line eradication treatments. The aim of this study was to compare the efficacy of metronidazole-containing regimens with that of metronidazole-free regimens after failure of first-line eradication using standard triple therapy.
View Article and Find Full Text PDFHELICOBACTER PYLORI ERADICATION TREATMENTS AND RISK OF ALZHEIMER DISEASE: A CASE-CONTROL STUDY NESTED IN THE FINNISH POPULATION.
Epidemiology
January 2025
School of Pharmacy, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Background: Helicobacter pylori (H. pylori) has been inconsistently associated with risk of Alzheimer disease. The exposure assessment period has often overlapped with the prodromal time of Alzheimer disease.
View Article and Find Full Text PDFEffect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of in Ningxia, China.
Front Med (Lausanne)
January 2025
Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
Introduction: () is becoming more resistant to antibiotics, and the implementation of individualized therapy is highly valuable for its eradication. This study aimed to investigate the efficacy and safety of individualized treatment guided by antibiotic susceptibility testing (AST) with a 10-day or 14-day course for the eradication of .
Methods: This was a prospective, open-label, single-center, quasi-randomized trial in which 220 participants were randomized into groups based on AST results as AST-10-day ( = 98) and AST-14-day ( = 112) treatment groups.
Antibiotic-free responsive biomaterials for specific and targeted Helicobacter pylori eradication.
J Control Release
January 2025
Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China; Shanghai Key Laboratory of Nautical Medicine and Translation of Drugs and Medical Devices, Shanghai, China. Electronic address:
Gastric cancer is highly correlated with Helicobacter pylori (H. pylori) infection. Approximately 50 % of the population worldwide is infected with H.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!